Dyne Therapeutics (DYN) PT Raised to $35 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DYN Hot Sheet
Price: $18.54 +2.71%
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Rating Summary:
16 Buy, 2 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 9 | Down: 14 | New: 1
Join SI Premium – FREE
RBC Capital analyst Luca Issi raised the price target on Dyne Therapeutics (NASDAQ: DYN) to $35.00 (from $30.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Progyny (PGNY) PT Raised to $38 at Citizens After Guidance Raise
- AUTO1 Group SE (AG1:GR) (ATOGF) PT Lowered to EUR26.40 at UBS
- Vistry Group PLC (VTY:LN) PT Lowered to GBP2.70 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
